Saturday, 14^th May 2005

8.00 – 12.00pm

Poster Discussion Session

Level 2, Hall F3

Brain Tumor Group

Multicentre Phase II Study of Imatinib Mesylate (Glivec^®) in Patients With Recurrent Anaplastic Oligodendroglioma (AOD)/Mixed Oligoastrocytoma (MOA) and Anaplastic Astrocytoma (AA)/Low Grade Astrocytoma (LGA): An EORTC: New Drug Development Group (NDDG) and Brain Tumor Group (BTG) Study).

Presenter: M. van den Bent, MD

Abstract N°: 1517

12.15 – 12.30pm

Oral Abstract Presentation Session

Level 4, Valencia Room, 415B

Soft Tissue and Bone Sarcoma Group

Assessment of molecular determinants of development and treatment efficacy in radiation induced sarcoma (RIS). EORTC STBSG Translational Research Project 01/01.

Presenter: P. Hohenberger, MD, PhD

Abstract N°: 9008

1.00 – 1.15pm

Oral Abstract Presentation Session

Level 2, Hall F5

Lymphoma Group

First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL).

Presenter: E.M. Noordijk, MD, PhD

Abstract N°: 6505

1.00 – 5.00pm

Poster Discussion Session

Level 2, Hall F3

Quality of Life Group

An international prospective study of the psychometric properties of the EORTC satisfaction with care measure (EORTC QLQ SAT-32). 

Presenter: A. Brédart

Abstract N°: 6030

2.00 – 6pm

Poster Discussion Session

Level 2, Hall C

Chronotherapy Group

Independent prognostic value of the rest/activity circadian rhythm on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCC) receiving first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin: a companion study to EORTC 05963.

Presenter: C. Garufi, MD

Abstract N°: 3553

2.00 – 6pm

Poster Discussion Session

Level 2, Hall C

Chronotherapy Group

Gender as a predictor for optimal dynamic scheduling of oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Results from EORTC randomized phase III trial 05963.

Presenter: F. Lévi, MD, PhD

Abstract N°: 3587

2.00 – 6pm

Poster Discussion Session

Level 2, Hall C

Gastrointestinal Tract Cancer Group

On behalf of the EORTC Gastrointestinal Tract Cancer Group: The value of patient-reported symptoms as prognostic factors for survival in advanced colorectal cancer.

Presenter: F. Efficace, PhD

Abstract N°: 3585

Sunday, 15^th May 2005

8.00 – 12.00pm

Poster Discussion Session

Level 2, Hall F4

Chronotherapy Group

Quality of life (QoL) correlates with the rest/activity circadian rhythm (RAR) in patients (pts) with metastatic colorectal cancer (MCC) on first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin : an international multicenter study (EORTC 05963).

Presenter: P.F. Innominato, MD

Abstract N°: 8029

8.00 – 12.00pm

Poster Discussion Session

Level 2, Hall C

Brain Tumor and Radiotherapy Groups

On behalf of the EORTC Brain tumor and Radiotherapy groups and NCIC: Predicting survival using health-related quality of life scores in glioblastoma cancers. Findings from an international Phase III randomized controlled trial.

Presenter: A. Bottomley, PhD

Abstract N°: 9601

8.00 – 12.00pm

Poster Discussion Session

Level 2, Hall C

Gastrointestinal Tract Cancer and Receptor and Biomarker Groups

Quality control (QC) tissue array for the prospective evaluation of translational research projects. A program of the EORTC GI and RB Groups.

Presenter: M.P. Lutz, MD

Abstract N°: 9600

Monday, 16^th May 2005

8.00 – 12.00pm

Poster Discussion Session

Level 2, Hall C

Soft Tissue and Bone Sarcoma Group

Exatecan (DX-8951f), a new topoisomerase I - inhibitor is inactive in heavily pretreated patients (pts.) with advanced soft tissue sarcoma (STS): a phase II - study of the EORTC Soft Tissue and Bone Sarcoma Group.

Presenter: P. Reichardt

Abstract N°: 9058

9.15 – 9.30am

Oral Abstract Presentation Session

Level 2, Hall A2

Radiotherapy Group

Preoperative radiation (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22921 trial.

Presenter: J.F. Bosset, MD

Abstract N°: 3505

1.00 – 1.15pm

Oral Abstract Presentation Session

Level 2, Hall A2

Lung Group

A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941).

Presenter: J.P. van Meerbeeck, MD, PhD

Abstract N°: LBA 7015

1.00 – 5pm

Poster Discussion Session

Level 2, Hall F3

Genito-Urinary Group

Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors.

Presenter: C.N. Sternberg, MD, FACP

Abstract N°: 4528

4.00 – 4.15pm

Plenary Session III

Level 2, Hall D2

Gastrointestinal Tract Cancer Group

Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3).

Presenter: E. van Cutsem, MD, Phd

Abstract N°: LBA8

Tuesday, 17^th May 2005

8.00 – 12.15pm

Poster Discussion Session

Level 3, 315 A

Gastrointestinal Tract Cancer Group

Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015.

Presenter: C.H. Köhne, MD

Abstract N°: 3525

8.00 – 12.15pm

Poster Discussion Session

Level 3, 315 A

Gastrointestinal Tract Cancer Group

Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983.

Presenter: B. Nordlinger, MD

Abstract N°: 3528

8.30 – 8.45am

Oral Abstract Presentation Session

Level 2, 230 A

Brain Tumor Group

First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma.

Presenter: M.J. van den Bent, MD

Abstract N°: 1503